TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03438695

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Motorized Spiral Enteroscopy
Description: Motorized Spiral endoscope will be inserted and advanced with the assistance of motorized clockwise spiral rotation, After reaching the cecum or if no further advancement of the endoscope can be achieved depth of insertion required for patient treatment or diagnosis, the endoscope will be withdrawn using motorized counter-clockwise spiral rotation, also controlled by the foot pedal. If no total enteroscopy was achieved, a submucosal ink dye injection is performed as an endoscopically visible marker of the maximum insertion depth. A retrograde peranal enteroscopy is then performed on one of the following days.
Study: NCT04762693

Intervention type: DEVICE
Intervention: Hyfe cough tracker
Description: A mobile app that runs in the background of smartphones and detects putative cough sounds.
Study: NCT00652223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT005-AllQbG10
Description: Immunomodulator CYT003-QbG10 in combination with commercial house dust mite extract as used for routine SIT
Study: NCT03117348

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Description: Patients in Gradual Goal-dose EN group will receive increased calories gradually by EN and will reach the 80% of target energy by EN at day 8 while patients in immediate Goal-dose EN group will receive 100% of target energy by EN at day 3 after abdominal surgery. Both of the two group will receive EN for 5 days except 80% of target energy delivered by oral feeding or patients are discharged from hospital, whichever arrives first.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Description: Patients in Gradual Goal-dose EN group will receive increased calories gradually by EN and will reach the 80% of target energy by EN at day 8 while patients in immediate Goal-dose EN group will receive 100% of target energy by EN at day 3 after abdominal surgery. Both of the two group will receive EN for 5 days except 80% of target energy delivered by oral feeding or patients are discharged from hospital, whichever arrives first.
Study: NCT02129101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonidegib
Description: Given PO
Study: NCT03917784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Oral supplementation with curcumin 500 mg oral dosing for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Starch
Description: Oral supplementation with starch 500 mg oral dosing for 3 months
Study: NCT02461095

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Impairment based approach
Description: This intervention will consist of exercise, mechanics training, education, manual therapy and modalities. The treatment will address the impairments found during the evaluation. This approach is a typical individualized physical therapy treatment approach.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PFPS Algorithm approach
Description: Physical Therapy treatment for Patellofemoral Pain Syndrome based upon a treatment algorithm that addresses patients: fear avoidance beliefs, flexibility, body mechanics, and strength. The exercises and treatments are individualized to each patient with the goals of low fear avoidance beliefs, flexibility, body mechanics, and strength and are performed in a sequential manner
Study: NCT01507636

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy
Description: Occupational therapy using a special arm function training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Physical therapy for arm force training.
Study: NCT00667472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser
Description: Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
Study: NCT03995784

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coagulation Factor IX variant
Description: Single intravenous injection of CB2679d/Dalcinonacog alfa

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Coagulation Factor IX variant
Description: Daily subcutaneous injections of CB2679d/Dalcinonacog alfa for 28 days
Study: NCT03018964

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Solo surgery
Description: Solo surgery using a camera scope holder in single incision laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: operation with a camera operator in SILC
Description: conventional single incision laparoscopic cholecystectomy with a scopist
Study: NCT03537079

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypoxia air
Description: Normobaric hypoxia is generated by adding azote in normal air to decrease the oxygen availability.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: hypoxia air
Description: Normobaric hypoxia is generated by adding azote in normal air to decrease the oxygen availability.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hypoxia air
Description: Normobaric hypoxia is generated by adding azote in normal air to decrease the oxygen availability.
Study: NCT03468959

Intervention type: BEHAVIORAL
Intervention: Maternal Supplemental PUFA Intake
Description: Maternal Supplemental PUFA Intake included sources from the questionnaires and plasma
Study: NCT00970541

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cinnamon Supplementation
Description: 1, 3, or 6g of cinnamon per day for 40 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (wheat flour)
Description: 1, 3, or 6g of placebo per day for 40 days
Study: NCT05541562

Intervention type: DIAGNOSTIC_TEST
Intervention: clinical laboratory tests, and imaging characteristics
Description: Data included the demographic status, etiology of the liver disease, clinical laboratory tests, and imaging characteristics. Clinical laboratory tests included D-dimer, activated partial thromboplastin time (APTT), prothrombin time (PT), antithrombin III, international normalized ratio (INR), thrombin time (TT), albumin (Alb), serum creatinine, hemoglobin, platelet count, white blood cell count, neutrophil count, lymphocyte count, monocyte count, model for end-stage liver disease (MELD) score, and Child-Pugh score. Imaging characteristics included splenic vein diameter, splenic vein velocity, portal vein diameter, and portal vein velocity.

Intervention type: DIAGNOSTIC_TEST
Intervention: clinical laboratory tests, and imaging characteristics
Description: Data included the demographic status, etiology of the liver disease, clinical laboratory tests, and imaging characteristics. Clinical laboratory tests included D-dimer, activated partial thromboplastin time (APTT), prothrombin time (PT), antithrombin III, international normalized ratio (INR), thrombin time (TT), albumin (Alb), serum creatinine, hemoglobin, platelet count, white blood cell count, neutrophil count, lymphocyte count, monocyte count, model for end-stage liver disease (MELD) score, and Child-Pugh score. Imaging characteristics included splenic vein diameter, splenic vein velocity, portal vein diameter, and portal vein velocity.
Study: NCT01738880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SVV
Description: During the surgery, patients in group S receive additional fluids (400 ml of normal saline or 200 ml of colloid) when SVV is less than 13.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVP
Description: Patients in group C receive additional fluids (400 ml of normal saline or 200 ml of colloid) when CVP is less 8 during the surgery.
Study: NCT02537639

Intervention type: DEVICE
Intervention: Transesophageal echocardiography simulator
Study: NCT01771393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CBCT prior to MDCT
Description: Cone-beam scanner is performed immediately after arthrography, then multidetector scanner is performed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDCT prior to CBCT
Description: Multidetector scanner is performed immediately after arthrography, then Cone-beam scanner is performed.
Study: NCT03988075

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen and hydrocodone based pain control
Description: Patients receive acetaminophen 650mg every 4 for pain level 1-3, hydrocodone/acetaminophen 5/325mg every 4 for pain level 4-6, or hydrocodone/acetaminophen 10/650mg every 4 for pain level 7-10 on as needed basis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acetaminophen and ibuprofen based pain control
Description: Patients receive standing dose of acetaminophen 650mg every 8 hours and ibuprofen 800mg every 8 hours with alternating ibuprofen and acetaminophen every 4 hours.
Study: NCT00834808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl
Description: One single oral administration of Tramadol HCl 100 mg, 200 mg or 300 mg as per randomization schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl
Description: One single oral administration of Tramadol HCl 100 mg, 200 mg or 300 mg as per randomization schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol HCl
Description: One single oral administration of Tramadol HCl 100 mg, 200 mg or 300 mg as per randomization schedule.
Study: NCT03675932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapid Cadence Cycling on a Solo-Rider Spin Bicycle
Description: Individuals with Parkinson's Disease will participate in 60 minute spin-classes during which they will follow the Pedaling for Parkinson's(TM) Foundation recommended protocol to achieve a cadence of 80-90 during the 40 minute main set.
Study: NCT01147484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foretinib
Description: foretinib, at a continuous oral daily dose of 60 mg
Study: NCT03072836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: analysing microbiota
Description: 16SRNA gene sequencing of feces

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: analysing microbiota
Description: 16SRNA gene sequencing of feces
Study: NCT01154569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 500 mg single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 500 mg single dose
Study: NCT03072836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: analysing microbiota
Description: 16SRNA gene sequencing of feces
Study: NCT03361423

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nerivio Migra-1 active device
Description: The device is placed on the subject upper arm. when activated, stimulus is applied to influence the subject's perception of a painful stimulus, delivered (or originating) at a different location. Based on diffused noxious inhibitory control mechanism, sometimes referred to as pain inhibits pain principle, conditioned pain modulation evokes an endogenous analgesic mechanism. The modulatory effect is over the whole body, and can be induced anywhere in the body. This approach allows applying the conditioning stimuli away from the painful site.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Nerivio Migra-1 Sham device
Description: The device is placed on the subject upper arm. when activated, the stimulus is applied is not sufficient to influence the subject's perception of a painful stimulus.
Study: NCT01568489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-009 Liposomal Gel
Description: a semi-transparent red-color gel and is supplied as a laminated tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-009 Liposomal Gel
Description: a semi-transparent red-color gel and is supplied as a laminated tube

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-009 Liposomal Gel
Description: a semi-transparent red-color gel and is supplied as a laminated tube
Study: NCT01620905

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Manipulation
Description: Single level cervical spine joint manipulation
Study: NCT01858467

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Portex endotracheal tube 6.5mm or 7.0mm internal diameter
Study: NCT01568489

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HL-009 Liposomal Gel
Description: a semi-transparent red-color gel and is supplied as a laminated tube
Study: NCT03028272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skye Barrier
Description: Substrate derived from amniotic tissue that is FDA-approved for human implantation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fascia
Description: Autologous donor substrate. Examples include tragal cartilage, perichondrium, temporalis fascia, and temporoparietal fascia
Study: NCT03252795

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uterus transplantation
Description: transplantation of a uterus from a deceased donor
Study: NCT03617484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered subcutaneously at a dose of 1.3 mg/m\^2 on days 1, 4, 8, and 11 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be administered orally at a dose of 560 mg daily for each 21 day cycle.
Study: NCT00297271

Intervention type: OTHER
Intervention: Current treatment practice of each participating physician
Description: Patients will be observed for the evaluation of current management strategies.
Study: NCT01765985

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PSORIAMED
Description: V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs.
Study: NCT00741676

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopy-assisted distal gastrectomy
Description: 10 mm trocar under umbilicus, 12 mm and 5 mm trocar at the right flank area are inserted into abdominal wall. Another two 5 mm trocar are inserted into the both midline of subcostal line. The devices for operation are inserted through the trocars. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. As a general rule, Billroth II method was used for gastric reconstruction for all cases.Dissected stomach and lymph node are collected through additional 3\~5 cm incision at the preexisting epigastric incision.Finally, Billroth II reconstruction is performed.
Study: NCT01765985

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PLACEBO
Description: V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.~V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.~V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs.
Study: NCT01841320

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated methadone and antiretroviral therapy (iMART) clinic
Study: NCT03876574

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DSA-guided implantation of hepatic artery infusion pump
Description: Implant the infusion catheter and injection port (Celsite, B. Braun, Chasseneuil, France) under DSA-guiding. The proximal end of the infusion catheter was connected to the injection port and the device was implanted in a subcutaneous pocket in the right inner thigh; the distal end of the infusion catheter guarantee uni-direction infusion to liver.
Study: NCT00741676

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open distal gastrectomy
Description: Approximately 15\~20 cm length incision is made from falciform process to periumbilical area. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. As a general rule, Billroth II method was used for gastric reconstruction for all cases.
Study: NCT01376986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical, psychological and social activation
Study: NCT02611271

Intervention type: OTHER
Intervention: Monitoring of antibiotic drug removal
Description: No study specific intervention will be performed

Intervention type: OTHER
Intervention: Monitoring of antibiotic drug removal
Description: No study specific intervention will be performed
Study: NCT03124589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Gambling Internet Intervention
Description: CAMH's online gambling intervention which includes self-help materials as well as a personalized feedback component.
Study: NCT00981214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUR-1008 (APT-1008)
Description: EUR-1008 (APT-1008) Microtabs contained in a capsule will be administered orally from Day 5 to Day 11 at an enzyme dose based on investigator's discretion, in dose stabilization period or the content of the capsule will be allowed to sprinkle on food, where necessary, followed by stabilized dose from Day 12 to Day 18 in treatment period, up to a maximum total dose of 10,000 lipase units per kilogram body weight per day (unit/kg/day).
Study: NCT01858467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supreme Laryngeal Mask Airway
Description: Supreme Laryngeal Mask Airway Size 3 or Size 4 with gastric tube insertion.
Study: NCT04131569

Intervention type: DIAGNOSTIC_TEST
Intervention: ESBL-E fecal carriage screening according to routine care
Description: ESBL-E fecal carriage screening according to routine care

Intervention type: DIAGNOSTIC_TEST
Intervention: ESBL-E fecal carriage screening according to routine care
Description: ESBL-E fecal carriage screening according to routine care
Study: NCT01921816

Intervention type: DEVICE
Group type: OTHER
Intervention: Prismocitrate 18/0, Prism0cal
Description: Subjects on continuous hemodiafiltration will ordinarily receive heparin as the anticoagulation. In our study, regional citrate anticoagulation with Prismacitrate is used to replace heparin. Citrate has been shown in study to be safer than heparin with reduced bleeding risk
Study: NCT02272725

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tasteless and inert visually identical (to ibuprofen) pills
Study: NCT06764550

Intervention type: OTHER
Intervention: This is an observational study, participants are not assigned an intervention as part of the study.
Description: This is an observational study, participants are not assigned an intervention as part of the study.

Intervention type: OTHER
Intervention: This is an observational study, participants are not assigned an intervention as part of the study.
Description: This is an observational study, participants are not assigned an intervention as part of the study.

Intervention type: OTHER
Intervention: This is an observational study, participants are not assigned an intervention as part of the study.
Description: This is an observational study, participants are not assigned an intervention as part of the study.
Study: NCT00810836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BG00012
Description: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BG00012
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral placebo
Study: NCT02031367

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Corticosteroid arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Platelet Rich Plasma
Study: NCT00656279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive dietary phosphorus education
Description: Intensive dietary phosphorus education will be completed using the Phosphorus Point System Tool, a booklet listing phosphorus points for food items based on the phosphorus content. Patients will be allotted a maximum of 32-40 phosphorus points daily. Points consumed will be tracked by the patients via daily tracking sheets which require patients to list the phosphorus food items consumed, the number of points, and the time and amount of phosphate binders. Patients in this group will also receive intensive education about phosphorus additives. As a part of the program that supports the tool, patients will receive weekly telephone calls for the first 6 weeks to address any questions about the tool and find phosphorus point values of foods not listed within the tool.
Study: NCT00514683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose BIBF1120 once daily
Description: low dose BIBF1120 once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose BIBF 1120 twice daily
Description: low dose BIBF 1120 twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intermediate dose BIBF 1120 twice daily
Description: intermediate dose BIBF 1120 twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose BIBF 1120 twice daily
Description: high dose BIBF 1120 twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo